- Home
- EAF vs HUMA Comparison
EAF vs HUMA Comparison
Compare EAF & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | HUMA |
|---|---|---|
| Founded | 1886 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 191.4M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EAF | HUMA |
|---|---|---|
| Price | $6.83 | $0.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $11.75 | $6.19 |
| AVG Volume (30 Days) | 275.8K | ★ 7.9M |
| Earning Date | 05-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | $2,038,000.00 |
| Revenue This Year | $4.25 | $444.16 |
| Revenue Next Year | $12.49 | $248.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.92 | $0.53 |
| 52 Week High | $20.32 | $2.55 |
Technical Indicators
Market Signals| Indicator | EAF | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 47.42 |
| Support Level | $6.16 | $0.63 |
| Resistance Level | $8.21 | $0.75 |
| Average True Range (ATR) | 0.43 | 0.06 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 15.88 | 55.65 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.